Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.
Company profile
Ticker
PFE
Exchange
Website
CEO
Albert Bourla
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
356 Royalty Inc. • Agouron Pharmaceuticals, LLC • AH Robins LLC • AHP Manufacturing B.V. • Alpharma Pharmaceuticals LLC • American Food Industries LLC • Amplyx Pharmaceuticals, Inc. • Anacor Pharmaceuticals, LLC • Arena Pharmaceuticals Canada Holdings, L.P. • Arena Pharmaceuticals Development GmbH ...
PFE stock data
Latest filings (excl ownership)
PX14A6G
Letter to shareholders
16 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
DEFA14A
Additional proxy soliciting materials
28 Mar 24
ARS
2023 FY
Annual report to shareholders
14 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Mar 24
DEF 14A
Definitive proxy
14 Mar 24
Transcripts
PFE
Earnings call transcript
2023 Q4
30 Jan 24
PFE
Earnings call transcript
2023 Q3
31 Oct 23
PFE
Earnings call transcript
2023 Q2
1 Aug 23
PFE
Earnings call transcript
2023 Q1
2 May 23
PFE
Earnings call transcript
2022 Q4
31 Jan 23
PFE
Earnings call transcript
2022 Q3
1 Nov 22
PFE
Earnings call transcript
2022 Q2
28 Jul 22
PFE
Earnings call transcript
2022 Q1
3 May 22
PFE
Earnings call transcript
2021 Q4
8 Feb 22
PFE
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.23 bn | 3.23 bn | 3.23 bn | 3.23 bn | 3.23 bn | 3.23 bn |
Cash burn (monthly) | (no burn) | (no burn) | 1.12 bn | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 7.61 bn | n/a | n/a | n/a |
Cash remaining | n/a | n/a | -4.38 bn | n/a | n/a | n/a |
Runway (months of cash) | n/a | n/a | -3.9 | n/a | n/a | n/a |
Institutional ownership, Q4 2023
48.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2453 |
Opened positions | 241 |
Closed positions | 642 |
Increased positions | 710 |
Reduced positions | 1358 |
13F shares | Current |
---|---|
Total value | 74.73 tn |
Total shares | 2.75 bn |
Total puts | 17.83 mm |
Total calls | 33.89 mm |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 506.52 mm | $14.58 tn |
STT State Street | 287.48 mm | $8.28 tn |
Wellington Management | 239.21 mm | $6.89 tn |
Capital World Investors | 173.39 mm | $4.99 tn |
Charles Schwab Investment Management | 104.25 mm | $2.99 tn |
MS Morgan Stanley | 82.11 mm | $2.36 tn |
Massachusetts Financial Services | 68.51 mm | $1.97 tn |
NTRS Northern Trust | 59.81 mm | $1.72 tn |
LGEN Legal & General | 49.62 mm | $1.43 tn |
BK Bank Of New York Mellon | 44.09 mm | $1.27 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | Jennifer B. Damico | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 25.91 | 54 | 1.40 k | 27,864 |
15 Apr 24 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 25.91 | 20 | 518.20 | 659,636 |
10 Apr 24 | Jennifer B. Damico | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 26.32 | 108 | 2.84 k | 27,806 |
10 Apr 24 | Albert Bourla | Phantom Stock Units SSP Common Stock | Grant | Acquire A | No | No | 26.32 | 18 | 473.76 | 659,517 |
28 Mar 24 | Narayen Shantanu | Phantom Stock Units Common Stock | Grant | Acquire A | No | No | 27.75 | 1,801.802 | 50.00 k | 134,402.012 |
News
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
23 Apr 24
Pfizer Options Trading: A Deep Dive into Market Sentiment
22 Apr 24
European Commission Approves Pfizer's EMBLAVEO For Patients With Multidrug-Resistant Infections And Limited Treatment Options
22 Apr 24
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
18 Apr 24
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff
16 Apr 24
Press releases
Pfizer Declares Second-Quarter 2024 Dividend
24 Apr 24
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
11 Apr 24
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
9 Apr 24
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
8 Apr 24
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
8 Apr 24